Efficacy of rituximab in anti-myelin-associated glycoprotein demyelinating polyneuropathy: Clinical, hematological and neurophysiological correlations during 2 years of follow-up.
Mattia ParisiIrene DogliottiMichele ClericoDavide BertuzzoGiulia BenevoloLorella OrsucciIrene SchiavettiRoberto CavalloFederica CavalloSimone RagainiAlessandra Di LibertoMartina FerranteGiulia BondielliCarlo Alberto ArtusiDaniela DrandiLeonardo LopianoBruno FerreroSimone FerreroPublished in: European journal of neurology (2022)
This study suggests that RTX is effective in patients with clinically active demyelinating anti-MAG neuropathy over 2 years of follow-up, and that some neurophysiological variables might be useful for monitoring this efficacy.
Keyphrases